FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2859364562> ?p ?o ?g. }

• W2859364562 endingPage "706" @default.
• W2859364562 startingPage "699" @default.
• W2859364562 abstract "Background Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline. Methods In this retrospective cohort study, we analysed patient data from the South African rifampicin-resistant tuberculosis case register (EDRweb), and identified additional mortality using the national vital statistics register. We excluded patients who started treatment before July 1, 2014, or after March 31, 2016; patients younger than 15 years or older than 75 years; patients without documented rifampicin resistance, and patients with pre-extensively drug-resistant tuberculosis (multidrug-resistant tuberculosis with further resistance to a second-line injectable or fluoroquinolone). We compared all-cause mortality between patients who received bedaquiline in treatment regimens and those who did not. Patients who did not receive bedaquiline had kanamycin or capreomycin and moxifloxacin as core medicines in their regimen. We estimated hazard ratios for mortality separately for multidrug-resistant or rifampicin-resistant tuberculosis and extensively drug-resistant tuberculosis and adjusted using propensity score quintile strata for the potential confounders of sex, age, HIV and antiretroviral therapy status, history of prior tuberculosis, valid identification number, and year and province of treatment. Findings 24 014 tuberculosis cases were registered in the EDRweb between July 1, 2014, and March 31, 2016. Of these, 19 617 patients initiated treatment and met our analysis eligibility criteria. A bedaquiline-containing regimen was given to 743 (4·0%) of 18 542 patients with multidrug-resistant or rifampicin-resistant tuberculosis and 273 (25·4%) of 1075 patients with extensively drug-resistant tuberculosis. Among 1016 patients who received bedaquiline, 128 deaths (12·6%) were reported, and there were 4612 deaths (24·8%) among 18 601 patients on the standard regimens. Bedaquiline was associated with a reduction in the risk of all-cause mortality for patients with multidrug-resistant or rifampicin-resistant tuberculosis (hazard ratio [HR] 0·35, 95% CI 0·28–0·46) and extensively drug-resistant tuberculosis (0·26, 0·18–0·38) compared with standard regimens. Interpretation Our retrospective cohort analysis of routinely reported data in the context of high HIV and extensively drug-resistant tuberculosis prevalence showed that bedaquiline-based treatment regimens were associated with a large reduction in mortality in patients with drug-resistant tuberculosis, compared with the standard regimen. Funding None." @default.
• W2859364562 created "2018-07-19" @default.
• W2859364562 creator A5009435222 @default.
• W2859364562 creator A5022980689 @default.
• W2859364562 creator A5027050469 @default.
• W2859364562 creator A5034322602 @default.
• W2859364562 creator A5049354356 @default.
• W2859364562 creator A5055249121 @default.
• W2859364562 creator A5060807835 @default.
• W2859364562 creator A5066635979 @default.
• W2859364562 creator A5072292499 @default.
• W2859364562 creator A5074418370 @default.
• W2859364562 creator A5078852155 @default.
• W2859364562 creator A5083781913 @default.
• W2859364562 date "2018-09-01" @default.
• W2859364562 modified "2023-10-16" @default.
• W2859364562 title "Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study" @default.
• W2859364562 cites W1768860766 @default.
• W2859364562 cites W1800998931 @default.
• W2859364562 cites W1956545035 @default.
• W2859364562 cites W1973053638 @default.
• W2859364562 cites W2098793988 @default.
• W2859364562 cites W2150291618 @default.
• W2859364562 cites W2160571788 @default.
• W2859364562 cites W2164918529 @default.
• W2859364562 cites W2171008074 @default.
• W2859364562 cites W2181828741 @default.
• W2859364562 cites W2197763760 @default.
• W2859364562 cites W2262666571 @default.
• W2859364562 cites W2318000940 @default.
• W2859364562 cites W2756021289 @default.
• W2859364562 cites W2765469364 @default.
• W2859364562 doi "https://doi.org/10.1016/s2213-2600(18)30235-2" @default.
• W2859364562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30001994" @default.
• W2859364562 hasPublicationYear "2018" @default.
• W2859364562 type Work @default.
• W2859364562 sameAs 2859364562 @default.
• W2859364562 citedByCount "182" @default.
• W2859364562 countsByYear W28593645622018 @default.
• W2859364562 countsByYear W28593645622019 @default.
• W2859364562 countsByYear W28593645622020 @default.
• W2859364562 countsByYear W28593645622021 @default.
• W2859364562 countsByYear W28593645622022 @default.
• W2859364562 countsByYear W28593645622023 @default.
• W2859364562 crossrefType "journal-article" @default.
• W2859364562 hasAuthorship W2859364562A5009435222 @default.
• W2859364562 hasAuthorship W2859364562A5022980689 @default.
• W2859364562 hasAuthorship W2859364562A5027050469 @default.
• W2859364562 hasAuthorship W2859364562A5034322602 @default.
• W2859364562 hasAuthorship W2859364562A5049354356 @default.
• W2859364562 hasAuthorship W2859364562A5055249121 @default.
• W2859364562 hasAuthorship W2859364562A5060807835 @default.
• W2859364562 hasAuthorship W2859364562A5066635979 @default.
• W2859364562 hasAuthorship W2859364562A5072292499 @default.
• W2859364562 hasAuthorship W2859364562A5074418370 @default.
• W2859364562 hasAuthorship W2859364562A5078852155 @default.
• W2859364562 hasAuthorship W2859364562A5083781913 @default.
• W2859364562 hasConcept C114851261 @default.
• W2859364562 hasConcept C126322002 @default.
• W2859364562 hasConcept C141071460 @default.
• W2859364562 hasConcept C142724271 @default.
• W2859364562 hasConcept C167135981 @default.
• W2859364562 hasConcept C207103383 @default.
• W2859364562 hasConcept C2776228421 @default.
• W2859364562 hasConcept C2776301714 @default.
• W2859364562 hasConcept C2777107064 @default.
• W2859364562 hasConcept C2777768864 @default.
• W2859364562 hasConcept C2777975735 @default.
• W2859364562 hasConcept C2778607973 @default.
• W2859364562 hasConcept C2780544761 @default.
• W2859364562 hasConcept C2781019175 @default.
• W2859364562 hasConcept C2781069245 @default.
• W2859364562 hasConcept C2781413609 @default.
• W2859364562 hasConcept C44249647 @default.
• W2859364562 hasConcept C71924100 @default.
• W2859364562 hasConcept C72563966 @default.
• W2859364562 hasConcept C86803240 @default.
• W2859364562 hasConcept C89423630 @default.
• W2859364562 hasConceptScore W2859364562C114851261 @default.
• W2859364562 hasConceptScore W2859364562C126322002 @default.
• W2859364562 hasConceptScore W2859364562C141071460 @default.
• W2859364562 hasConceptScore W2859364562C142724271 @default.
• W2859364562 hasConceptScore W2859364562C167135981 @default.
• W2859364562 hasConceptScore W2859364562C207103383 @default.
• W2859364562 hasConceptScore W2859364562C2776228421 @default.
• W2859364562 hasConceptScore W2859364562C2776301714 @default.
• W2859364562 hasConceptScore W2859364562C2777107064 @default.
• W2859364562 hasConceptScore W2859364562C2777768864 @default.
• W2859364562 hasConceptScore W2859364562C2777975735 @default.
• W2859364562 hasConceptScore W2859364562C2778607973 @default.
• W2859364562 hasConceptScore W2859364562C2780544761 @default.
• W2859364562 hasConceptScore W2859364562C2781019175 @default.
• W2859364562 hasConceptScore W2859364562C2781069245 @default.
• W2859364562 hasConceptScore W2859364562C2781413609 @default.
• W2859364562 hasConceptScore W2859364562C44249647 @default.
• W2859364562 hasConceptScore W2859364562C71924100 @default.
• W2859364562 hasConceptScore W2859364562C72563966 @default.
• W2859364562 hasConceptScore W2859364562C86803240 @default.

• next